Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retifanlimab + Radiation +/- Temozolomide in Newly-Diagnosed Glioblastoma
NCT05083754Phase 1Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Aug 2022
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of retifanlimab in glioblastoma multiforme (GBM) (3 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Safety of combination retifanlimab and radiation with and without temozolomide up to 2 years, Feasibility of combination retifanlimab and radiation with and without temozolomide up to 2 years and 1 more. Started Aug 2022; status: recruiting.
02
Drugs
retifanlimab
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT05083754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05083754.